• Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 73.52 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.83 (8.20%)

This chart shows the closing price for NEO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeoGenomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NEO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NEO

Analyst Price Target is $19.00
▲ +73.52% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $19.00, with a high forecast of $30.00 and a low forecast of $12.00. The average price target represents a 73.52% upside from the last price of $10.95.

This chart shows the closing price for NEO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 contributing investment analysts is to buy stock in NeoGenomics. This rating has held steady since September 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2022CowenLower Target$17.00Low
11/14/2022Piper SandlerLower TargetOverweight$19.00 ➝ $18.00Low
11/11/2022Raymond JamesLower TargetOutperform$15.00 ➝ $12.00Low
11/9/2022SVB LeerinkBoost TargetOutperform$12.00 ➝ $15.00Low
11/9/2022Morgan StanleyLower TargetEqual Weight$18.00 ➝ $17.00Low
10/28/2022William BlairReiterated RatingOutperformLow
8/26/2022BenchmarkDowngradeBuy ➝ HoldLow
8/22/2022Needham & Company LLCDowngradeBuy ➝ HoldLow
8/17/2022Piper SandlerBoost TargetOverweight$13.00 ➝ $19.00Low
8/15/2022CowenBoost Target$18.00N/A
8/15/2022BTIG ResearchDowngradeNeutralN/A
8/10/2022The Goldman Sachs GroupBoost TargetBuy$18.00 ➝ $20.00Low
8/10/2022Morgan StanleyLower TargetEqual Weight$19.00 ➝ $18.00Low
8/10/2022Needham & Company LLCLower TargetBuy$19.00 ➝ $16.00Low
7/19/2022CowenSet Target$17.00Low
6/2/2022Piper SandlerInitiated CoverageOverweight$13.00High
4/18/2022Raymond JamesLower TargetOutperform$24.00 ➝ $18.00High
4/12/2022Morgan StanleyLower TargetEqual Weight$29.00 ➝ $27.00Medium
3/29/2022CowenLower TargetOutperform$42.00 ➝ $24.00High
3/29/2022BTIG ResearchLower TargetBuy$35.00 ➝ $28.00High
3/29/2022BenchmarkLower Target$26.00 ➝ $16.00High
3/29/2022SVB LeerinkLower TargetOutperform$45.00 ➝ $20.00High
3/29/2022Needham & Company LLCLower TargetBuy$29.00 ➝ $19.00High
3/29/2022StephensDowngradeOverweight ➝ Equal Weight$34.00 ➝ $16.00High
3/29/2022Bank of AmericaDowngradeBuy ➝ Neutral$25.00 ➝ $18.00High
2/24/2022Craig HallumLower Target$46.00 ➝ $30.00High
2/24/2022Morgan StanleyLower TargetEqual Weight$30.00 ➝ $29.00High
2/24/2022Raymond JamesLower TargetOutperform$53.00 ➝ $24.00High
2/24/2022Needham & Company LLCLower TargetBuy$41.00 ➝ $29.00High
1/12/2022SVB LeerinkLower TargetOutperform$50.00 ➝ $45.00High
12/16/2021CowenInitiated CoverageOutperform$42.00High
12/7/2021Needham & Company LLCLower TargetBuy$48.00 ➝ $41.00High
11/5/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$58.00 ➝ $45.00High
11/5/2021StephensLower TargetOverweight$60.00 ➝ $53.00High
11/5/2021Needham & Company LLCLower TargetBuy$55.00 ➝ $48.00High
11/5/2021SVB LeerinkLower TargetOutperform$63.00 ➝ $60.00High
10/14/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$53.00High
8/26/2021BenchmarkBoost TargetBuy$46.00 ➝ $50.00High
8/9/2021Morgan StanleyLower TargetOverweight$64.00 ➝ $58.00High
8/9/2021Needham & Company LLCReiterated RatingBuy$55.00Medium
7/13/2021Needham & Company LLCInitiated CoverageBuy$55.00Low
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$55.00Low
4/16/2021Needham & Company LLCReiterated RatingBuy$65.00Medium
3/3/2021Raymond JamesReiterated RatingOutperform ➝ Market PerformN/A
2/25/2021Craig HallumBoost TargetIn-Line ➝ Buy$50.00 ➝ $65.00Low
2/25/2021Morgan StanleyBoost TargetOverweight$46.00 ➝ $64.00High
2/25/2021Needham & Company LLCInitiated CoverageBuy$65.00High
2/25/2021Needham & Company LLCReiterated RatingBuy$65.00High
2/25/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
1/27/2021Truist FinancialInitiated CoverageBuy$65.00Low
1/8/2021SVB LeerinkBoost TargetOutperform$50.00 ➝ $60.00High
12/11/2020BTIG ResearchInitiated CoverageBuyLow
11/20/2020SVB LeerinkBoost TargetOutperform$47.00 ➝ $50.00High
10/28/2020Craig HallumBoost TargetBuy$42.00 ➝ $50.00Low
10/28/2020Raymond JamesBoost TargetOutperform$40.00 ➝ $48.00Medium
10/28/2020BenchmarkBoost TargetBuy$40.00 ➝ $48.00High
10/28/2020Needham & Company LLCBoost TargetAverage ➝ Buy$39.00 ➝ $46.00High
10/28/2020SVB LeerinkBoost TargetOutperform$45.00 ➝ $47.00High
10/26/2020CIBCUpgradeOutperformer$10.50 ➝ $14.50Medium
9/9/2020Morgan StanleyInitiated CoverageOverweight$46.00High
8/28/2020GuggenheimInitiated CoverageBuy$46.00Medium
7/29/2020Craig HallumBoost TargetIn-Line ➝ Buy$36.00 ➝ $42.00Low
7/29/2020SVB LeerinkBoost TargetOutperform$35.00 ➝ $45.00Low
7/29/2020Raymond JamesBoost TargetOutperform$32.00 ➝ $40.00Medium
7/29/2020BenchmarkBoost TargetBuy$35.00 ➝ $40.00High
7/29/2020Needham & Company LLCBoost TargetBuy$33.00 ➝ $39.00High
6/25/2020Bank of AmericaInitiated CoverageBuy$34.00High
5/27/2020Needham & Company LLCReiterated RatingBuy$33.00High
5/15/2020CIBCDowngradeNeutral$11.00 ➝ $9.00Low
4/29/2020SVB LeerinkReiterated RatingBuy$33.00 ➝ $35.00High
4/29/2020Needham & Company LLCReiterated RatingBuy$33.00High
4/21/2020StephensInitiated CoverageOverweight$33.00High
3/17/2020Needham & Company LLCBoost TargetBuy$32.00 ➝ $33.00High
3/2/2020Craig HallumInitiated CoverageBuy$38.00Low
3/2/2020Raymond JamesBoost TargetOutperform$28.00 ➝ $32.00High
2/28/2020BenchmarkBoost TargetAccumulate ➝ Buy$27.00 ➝ $30.00Medium
2/28/2020Needham & Company LLCBoost TargetBuy$29.00 ➝ $32.00Medium
2/28/2020First AnalysisUpgradeOutperform ➝ Strong-Buy$35.00High
1/23/2020First AnalysisDowngradeStrong-Buy ➝ Outperform$29.00 ➝ $35.00Low
1/3/2020Needham & Company LLCInitiated CoverageBuy$14.00Low
10/30/2019Needham & Company LLCBoost TargetBuy$27.00 ➝ $29.00High
10/29/2019William BlairReiterated RatingOutperformLow
7/31/2019SVB LeerinkSet TargetBuy$30.00Medium
7/31/2019Needham & Company LLCSet TargetBuy$27.00Medium
7/31/2019BenchmarkSet TargetBuy$27.00Medium
7/31/2019Raymond JamesBoost TargetOutperform$23.00 ➝ $27.00Medium
5/1/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $24.00High
3/29/2019Needham & Company LLCBoost TargetBuy ➝ Buy$19.00 ➝ $22.00High
3/12/2019CIBCUpgradeNeutral ➝ Outperform$18.00 ➝ $15.00Medium
1/3/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$14.00High
12/4/2018Raymond JamesReiterated RatingBuy$24.00High
11/16/2018ScotiabankReiterated RatingBuy ➝ Average$24.00Low
11/1/2018BenchmarkSet TargetBuy$22.00Medium
10/31/2018Raymond JamesBoost TargetOutperform ➝ Buy$16.00 ➝ $21.00Low
10/31/2018Craig HallumBoost TargetBuy$17.00 ➝ $22.00Medium
9/18/2018First AnalysisSet TargetBuy$16.00High
8/21/2018SVB LeerinkInitiated CoverageOutperform$18.00High
6/26/2018StephensReiterated RatingBuy$15.00Medium
6/21/2018BTIG ResearchReiterated RatingBuy$15.00High
5/2/2018First AnalysisDowngradeOverweight ➝ Equal Weight$11.00Medium
4/16/2018BTIG ResearchUpgradeNeutral ➝ OutperformHigh
3/13/2018Royal Bank of CanadaBoost TargetOutperform$23.00 ➝ $24.00Medium
3/13/2018ScotiabankBoost TargetOutperform$22.00 ➝ $23.00Medium
1/3/2018Royal Bank of CanadaSet TargetOutperform$23.00Low
1/3/2018ScotiabankSet TargetOutperform$22.00Low
1/3/2018CIBCSet TargetNeutral$19.00Low
(Data available from 11/30/2017 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
NeoGenomics logo
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Read More

Today's Range

Now: $10.95
Low: $9.97
High: $10.96

50 Day Range

MA: $8.65
Low: $6.45
High: $11.26

52 Week Range

Now: $10.95
Low: $6.00
High: $36.89


33,330 shs

Average Volume

1,323,800 shs

Market Capitalization

$1.38 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of NeoGenomics?

The following Wall Street sell-side analysts have issued research reports on NeoGenomics in the last year: Bank of America Co., Benchmark Co., BTIG Research, Cowen Inc, Cowen Inc., Craig Hallum, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Stephens, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for NEO.

What is the current price target for NeoGenomics?

13 Wall Street analysts have set twelve-month price targets for NeoGenomics in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 83.0%. Craig Hallum has the highest price target set, predicting NEO will reach $30.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $12.00 for NeoGenomics in the next year.
View the latest price targets for NEO.

What is the current consensus analyst rating for NeoGenomics?

NeoGenomics currently has 6 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NEO will outperform the market and that investors should add to their positions of NeoGenomics.
View the latest ratings for NEO.

What other companies compete with NeoGenomics?

How do I contact NeoGenomics' investor relations team?

NeoGenomics' physical mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company's listed phone number is (239) 768-0600 and its investor relations email address is [email protected] The official website for NeoGenomics is www.neogenomics.com. Learn More about contacing NeoGenomics investor relations.